Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.45 |
| ▸ | GABRP | O00591 | 2/20 | 0.44 |
| ▸ | GABRD | O14764 | 2/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.44 |
| ▸ | GABRE | P78334 | 2/20 | 0.44 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.44 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.44 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.44 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25895556 | 0.83 | NAPRT (0.39) | KDM4EMAPTCYP1A2SHMT2NAPRT | |
| SCHEMBL15942046 | 0.82 | ADORA3 (0.49) | KDM4EMAPTCYP1A2TDP1ALDH1A1 | |
| SCHEMBL18989971 | 0.81 | SHMT2 (0.50) | KDM4EMAPTCYP1A2SHMT2NAPRT | |
| SCHEMBL15709787 | 0.79 | ALDH1A1 (0.44) | KDM4EMAPTSHMT2ALDH1A1L3MBTL1 | |
| SCHEMBL21437758 | 0.78 | ALDH1A1 (0.59) | KDM4EMAPTCYP1A2NAPRTTDP1 | |
| SCHEMBL11147053 | 0.78 | KDM4E (0.65) | KDM4EMAPTCYP1A2NAPRTTDP1 | |
| SCHEMBL30546480 | 0.77 | AKR1B1 (0.52) | KDM4EMAPTCYP1A2NAPRTTDP1 | |
| SCHEMBL2782918 | 0.77 | KDM4E (0.62) | KDM4EMAPTCYP1A2NAPRTTDP1 | |
| SCHEMBL29781414 | 0.77 | KDM4E (0.49) | KDM4EMAPTCYP1A2NAPRTTDP1 | |
| SCHEMBL3611719 | 0.77 | AKR1B1 (0.52) | KDM4EMAPTCYP1A2NAPRTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117534613-A | Preparation method of 3-aminopyridine-2-carboxylic acid methyl ester | 武威广达科技有限公司 | 2024-02-09 | — | — | CN | claimed |
| CN-117126084-A | Process for the preparation of cyclosulfones | 安徽久易农业股份有限公司 | 2023-11-28 | — | — | CN | claimed |
| CN-117534613-A | Preparation method of 3-aminopyridine-2-carboxylic acid methyl ester | 武威广达科技有限公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-117126084-A | Process for the preparation of cyclosulfones | 安徽久易农业股份有限公司 | 2023-11-28 | — | — | CN | disclosed |
| US-20160159808-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
| EP-3026051-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-06-01 | — | — | EP | disclosed |
| CN-103153997-B | Quinazoline derivatives | MERCK PATENT GMBH | 2015-04-29 | — | — | CN | disclosed |
| CN-104395297-A | Sulfonamide derivatives and pharmaceutical use thereof | AJINOMOTO KK | 2015-03-04 | — | — | CN | disclosed |
| CN-103153997-A | Quinazoline derivatives | MERCK PATENT GMBH | 2013-06-12 | — | — | CN | disclosed |
| CN-102099351-A | 3-heterocyclic substituted indole derivatives and methods of use thereof | SCHERING CORP | 2011-06-15 | — | — | CN | disclosed |
| CN-1902201-A | Bicyclic pyrimidin-4-(3H)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (VR1) | MERCK SHARP & DOHME (GB) | 2007-01-24 | — | — | CN | disclosed |
| US-20030225131-A1 | Thrombin inhibitors | BURGEY CHRISTOPHER S (US) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225131-A1 | Thrombin inhibitors | TFPI, SERPINC1, PLAT | KDM4E 2998/4885MAPT 3769/4885CYP1A2 3346/4885 |
| US-20160159808-A1 | HETEROCYCLIC COMPOUND | PDE2A, PDE3A, PDE5A | KDM4E 1323/4885MAPT 501/4885CYP1A2 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.